Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | BRAF | P15056 | 3/20 | 0.55 |
| ▸ | ABL1 | P00519 | 4/20 | 0.53 |
| ▸ | RET | P07949 | 8/20 | 0.53 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 6/20 | 0.50 |
| ▸ | CSF1R | P07333 | 4/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15847641 | 0.93 | EGFR (0.54) | EGFRBRAFABL1RETBCR | |
| SCHEMBL15859839 | 0.91 | EGFR (0.58) | EGFRBRAFABL1RETBCR | |
| SCHEMBL17426706 | 0.90 | CHRM3 (0.46) | EGFRBRAFABL1RET | |
| SCHEMBL15859875 | 0.85 | ABL1 (0.56) | EGFRBRAFABL1RETBCR | |
| SCHEMBL15847673 | 0.85 | EGFR (0.59) | EGFRBRAFABL1RETBCR | |
| SCHEMBL15859840 | 0.84 | BRAF (0.61) | EGFRBRAFABL1BCRKIT | |
| SCHEMBL15859863 | 0.84 | BRAF (0.52) | EGFRBRAFABL1BCRKIT | |
| SCHEMBL17420244 | 0.84 | EGFR (0.52) | EGFRBRAFABL1RETKIT | |
| SCHEMBL15859861 | 0.84 | BRAF (0.60) | EGFRBRAFABL1BCRKIT | |
| SCHEMBL15859862 | 0.84 | ABL1 (0.55) | EGFRBRAFABL1RETBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | EGFR 738/4885BRAF 32/4885ABL1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.